Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, which integrates the data from two clinical trials, highlights the safety profile, immune response and clinical activity of NEUVENGE in patients with HER2/neu-positive cancer who have failed standard therapy.

"We are encouraged by the significant immune responses generated to NEUVENGE in these trials, which included patients with advanced breast, ovarian and colon cancer," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco. "The therapy was well tolerated and demonstrated evidence of clinical activity, with several patients experiencing prolonged periods of disease stabilization following treatment. These findings warrant further study of this promising immunotherapy."

The two Phase 1 studies (D2000-1 and D2000-2) were designed to evaluate the safety and immunologic activity of NEUVENGE in patients with metastatic HER2/neu-expressing cancer who had evidence of progressive disease following standard therapies. Patients underwent three infusions of NEUVENGE over an approximately one month period. Patients who achieved a partial response, or had stable disease lasting through Week 48, were eligible for re-treatment with a booster, using the same protocol and dose as the initial treatment.

A total of 37 patients were treated. Results from the integrated analysis showed that treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fatigue, fever and chills. The median T cell proliferative stimulation index in response to the immunizing antigen increased from 1.3 at baseline to 19.7 at Week 4 (p = 0.0002), 19.4 at Week
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013  As the Share Repurchase Resolution has ... Offer for Elan Corporation, plc (NYSE: ELN ) ... outcome of the Proceedings referred to below and any consequent ... to be effective to the extent that it would have ... of the Share Repurchase Resolution being passed. There can be ...
(Date:6/17/2013)... PARSIPPANY, N.J. , June 17, 2013 Actavis, ... United States Supreme Court has reversed the decision of the ... affirmed the District Court,s ruling granting Actavis, motion to dismiss ... .  The Supreme Court,s reversal was the result of a ... the FTC,s proposed "quick look" approach and adopted the traditional ...
(Date:6/17/2013)... , June 17, 2013 The Biozoom ... portable, hand held device for the non-invasive transdermal ... human body. It replaces expensive, time consuming and ... a button, the Biozoom scanner reflects a beam ... Zeiss—and measures the reflection. Using the scanner, researchers ...
Breaking Medicine Technology:Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 2Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 3Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 4Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 5Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 6Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 7Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 8Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 9Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 10U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 2U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 3University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work 2University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work 3University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work 4
... Sheffield Bio-Science, a leading global pharmaceutical supplier of superior ... markets, has been awarded the distinguished 2010 Lilly Global Supplier Award. ... The ... and services for Eli Lilly and Company over the years and ...
... ATLANTA , July 12 Holon, the new ... Medication Management solution. , ... Leveraging the Holon Process Adaptive Interoperability Framework, ... your current medication management solution by automating the collection and ...
Cached Medicine Technology:Sheffield Bio-Science Wins 2010 Lilly Global Supplier Award 2Holon: The Process Adaptive Interoperability Framework 2
(Date:6/17/2013)... Essential tremor (ET) is the most common ... people in the United States, and millions more worldwide. ... causes ET, there are no medications specifically designed to ... Tremor© is the International Essential Tremor Foundation’s annual research ... cure for this life-altering neurological condition. , “Although millions ...
(Date:6/17/2013)... of people who registered themselves as organ donors 21-fold ... social media might be an effective tool to address ... The gains were made in May 2012 when the ... share their organ donor status with friends and provided ... department of motor vehicle websites. The findings are being ...
(Date:6/17/2013)... June 17, 2013 Bust’DD (pronounced ‘busted’), a ... and well-fitting to women with large busts, will soon launch ... two women who understand the problem of ill-fitting bras and ... women. Their goal is to raise at least $25,000 to ... offering their bras on a wide scale. , In order ...
(Date:6/17/2013)... 2013 The producers of Impact with ... of reports highlighting how sustainable farming techniques are helping ... and their demand on food supplies. , Impact ... series airing in markets around the country on public ... Sheen, who is marking the start of his second ...
(Date:6/17/2013)... As da Vinci robot lawsuit claims ... Liebhard LLP notes that a recent report aired on ... disturbing robotic surgery complications alleged to have been caused by ... June 14th broadcast revealed that the U.S. Food & Drug ... Vinci patients who suffered burns, cuts and infections since 2007. ...
Breaking Medicine News(10 mins):Health News:International Essential Tremor Foundation Kicks Off Annual Essential Tremor Research Fundraiser, Tulips for Tremor 2Health News:The Facebook effect: Social media dramatically boosts organ donor registration 2Health News:The Facebook effect: Social media dramatically boosts organ donor registration 3Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 3
... the Children of Love Canal Are Not Counted In the ... Speak &,Ask What Have We Learned?, FALLS CHURCH, Va., ... for Health, Environment & Justice:, WHAT:, Press Conference ... Love Canal once stood., Rain or Shine, WHEN:, ...
... YORK, July 26, 2008 The following news tips are ... 2008 International Conference to be held in Chicago from July ... specific date and time. , Brain Atrophy and Biomarkers ... Susan de Santi, Ph.D., Associate Professor, Department of Psychiatry, NYU ...
... FE SPRINGS, Calif., July 29 IQAir announced ... (USOC) with ultra-high,efficiency air cleaning for USA athletes ... the optimum performance environment., (Photo: http://www.newscom.com/cgi-bin/prnh/20080729/LATU099 ... able to support the performance efforts of the,USOC ...
... SAN JOSE, Calif., July 29 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... for the full year 2008. Full-year 2008 net income is ... income of $0.77,to $0.85 per share which is changed from ... or income of $0.68 to $0.74 per,share., ABOUT VNUS ...
... AGAWAM, Mass., July 29 Microtest Laboratories has,launched ... compounding pharmacies,in the U.S. that have yet failed ... 797) regulations. Microtest also announced,its offer of a ... USP 797 compliance level and corresponding,preparation., Pharmacies ...
... Health and Charitable Care and Coverage, OAKLAND, ... it has approved more than 415 community benefit ... second quarter of 2008.,The quarter,s contributions continue to ... a measurable impact on the health of,its communities., ...
Cached Medicine News:Health News:30 Years After State of Emergency Declared at Love Canal, NY Closing the 99th Street School Triggering the Federal Superfund Program; Schools & Communities Across the Nation Still at Risk of Toxic Contamination 2Health News:New Alzheimer's predictors advance earlier detection 2Health News:New Alzheimer's predictors advance earlier detection 3Health News:New Alzheimer's predictors advance earlier detection 4Health News:New Alzheimer's predictors advance earlier detection 5Health News:New Alzheimer's predictors advance earlier detection 6Health News:New Alzheimer's predictors advance earlier detection 7Health News:New Alzheimer's predictors advance earlier detection 8Health News:IQAir to Provide U.S. Athletes With Ultra-High Efficiency Air Cleaning at the Beijing 2008 Olympic Games 2Health News:VNUS Revises Upward Full-Year 2008 Net Income Guidance 2Health News:Microtest Offers New Services, Free Facility Audit, for Compounding Pharmacies Seeking USP 797 Compliance 2Health News:Microtest Offers New Services, Free Facility Audit, for Compounding Pharmacies Seeking USP 797 Compliance 3Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 3
... The QuickVue Influenza A+B test allows ... influenza type A and type B ... wash and/or nasal aspirate specimens. The ... in the rapid differential diagnosis of ...
... Antibody Detection Assay is a single use, ... (first step) detection of IgG and IgM ... or whole blood. Rapid turnaround time, ease ... Wampole PreVue B. burgdorferi antibody detection test ...
... Conforming to U.S. and international ... Nephew's TC-100 Screw and Plating System* ... and ease of use for open ... However, the TC-100 system works well ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: